Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Other Operating Expenses (2024 - 2025)

Kymera Therapeutics (KYMR) has disclosed Other Operating Expenses for 4 consecutive years, with $3.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to $3.9 million in Q3 2025 year-over-year; TTM through Dec 2025 was $3.9 million, a 21.73% decrease, with the full-year FY2025 number at $3.9 million, down 21.73% from a year prior.
  • Other Operating Expenses was $3.9 million for Q3 2025 at Kymera Therapeutics, down from $4.9 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $4.9 million in Q1 2024 to a low of -$1000.0 in Q2 2022.
  • A 3-year average of $2.9 million and a median of $3.9 million in 2025 define the central range for Other Operating Expenses.